Vaxxinity, Inc. (VAXX)
Vaxxinity, Inc., a biotechnology company founded in 2014 and headquartered in Dallas, Texas, is dedicated to advancing novel therapeutic candidates for human application in the United States. Its primary areas of focus are neurological disorders and infectious diseases, particularly those caused by coronaviruses. The company's pipeline features several key programs: UB-311 is a Phase 2 clinical trial candidate targeting toxic aggregated amyloid-beta proteins in the brain, aiming to treat Alzheimer's disease. UB-312, currently in Phase 1 clinical trials, is an investigational therapy designed to address Parkinson's disease and other synucleinopathies, including Lewy body dementia and multiple system atrophy, by targeting detrimental aggregated alpha-synuclein. An anti-tau product candidate is also under development for various neurodegenerative conditions, such as Alzheimer's disease. UB-313 is being developed to alleviate migraines by modulating calcitonin gene-related peptide. An anti-PCSK9 candidate aims to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events by targeting proprotein convertase subtilisin/kexin type 9 serine protease. In the infectious disease segment, UB-612 is a Phase 3 clinical-stage candidate engineered to neutralize the SARS-CoV-2 virus.
Sector: Biotechnology
Industry: Biotechnology
Vaxxinity, Inc.
No splits on record
Nothing in VAXX's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $0 | $0 | $66K | $557K | $0 |
| YoY Growth | - | - | -88.2% | - | - |
| Cost of Revenue | $2.23M | $1.68M | $1.94M | $52K | $107K |
| Gross Profit | -$2.23M | -$1.68M | -$1.87M | $505K | -$107K |
| Gross Margin | - | - | -2834.8% | 90.7% | - |
| Research and Development | $33.66M | $47.63M | $71.38M | $20.57M | $10.66M |
| Selling, General, and Administrative | $22.39M | $28.35M | $51.83M | $12.22M | $3M |
| Other | $0 | -$1.68M | $0 | $0 | $0 |
| Total Operating Expenses | $56.05M | $74.3M | $123.2M | $32.79M | $13.66M |
| Operating Income (EBIT) | -$58.28M | -$75.98M | -$125.08M | -$32.28M | -$13.66M |
| Operating Margin | - | - | -189507.6% | -5795.7% | - |
| Interest Expense | $696K | $514K | $840K | $1.18M | $435K |
| Interest Income | $2.09M | $1.26M | $9K | $0 | $435K |
| Other Income (Expense) | $1.35M | $757K | -$12.1M | -$7.67M | -$502K |
| Income Before Tax (EBT) | -$57K | -$75.22M | -$137.18M | -$39.96M | -$14.16M |
| Income Tax Expense | $0 | -$12K | $0 | $0 | $56K |
| Net Income | -$57K | -$75.21M | -$137.18M | -$39.96M | -$14.22M |
| Net Income Margin | - | - | -207840.9% | -7173.6% | - |
| Supplementary Data | |||||
| EPS | -0.00 | -0.60 | -1.09 | -0.32 | -0.11 |
| Diluted EPS | -0.00 | -0.60 | -1.09 | -0.32 | -0.11 |
| Weighted Average OS | 126.51M | 125.94M | 125.39M | 125.45M | 125.45M |
| EBITDA | -$54M | -$73.02M | -$135.23M | -$38.06M | -$13.58M |
| EBITDA Margin | - | - | -204898.5% | -6832.7% | - |
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $4.93M | $33.48M | $144.88M | $31.14M | $476K |
| Short-Term Investments | $25.46M | $53.35M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $30.39M | $86.83M | $144.88M | $31.14M | $476K |
| Accounts Receivable | $414K | $414K | $393K | $387K | $303K |
| Inventory | $0 | $6.12M | $0 | $3.31M | $0 |
| Other Current Assets | $945K | $522K | $341K | $4.14M | $656K |
| Total Current Assets | $33.23M | $93.89M | $154.13M | $35.67M | $1.44M |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $11.08M | $12.51M | $12.37M | $12.16M | $160K |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $172K | $0 | $0 |
| Deferred Tax Assets | $0 | $84K | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | -$84K | $0 | $2.31M | $0 |
| Total Long-Term Assets | $11.08M | $12.51M | $12.54M | $14.47M | $160K |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $44.31M | $106.4M | $166.67M | $50.14M | $1.59M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $1.78M | $5.29M | $3.19M | $9.02M | $1.28M |
| Short-Term Debt | $1.91M | $1.5M | $376K | $27.59M | $13.19M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $1.56M | $11.37M | $4.52M | $53K | $0 |
| Total Current Liabilities | $17.61M | $30.94M | $27.49M | $37.22M | $19.88M |
| Long-Term Liabilities | |||||
| Long-Term Debt | $13.26M | $13.04M | $10.32M | $10.7M | $1.15M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $65.01M | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $236K | $236K | $236K | $236K |
| Other Long-Term Liabilities | $35K | -$1 | $237K | $24.34M | $28.85M |
| Total Long-Term Liabilities | $13.3M | $13.28M | $10.56M | $100.29M | $30.23M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $30.9M | $44.22M | $38.05M | $137.52M | $50.11M |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $62.48M | $26.82M |
| Common Stock | $278K | $278K | $278K | $272K | $270K |
| Retained Earnings | -$361.64M | -$304.7M | -$229.48M | -$92.31M | -$52.35M |
| Comprehensive Income & Other | $8K | -$197K | $0 | -$62.48M | -$26.82M |
| Other Stockholders' Equity | $374.77M | $366.6M | $357.82M | $4.66M | $3.57M |
| Total Equity | $13.41M | $62.18M | $128.62M | -$87.38M | -$48.51M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $44.31M | $106.4M | $166.67M | $50.14M | $1.59M |
| Supplementary Data | |||||
| Total Debt | $15.17M | $14.55M | $10.7M | $38.3M | $14.33M |
| Net Debt | $10.24M | -$18.93M | -$134.19M | $7.16M | $13.86M |
| Period | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||
| Net Income | -$56.93M | -$75.22M | -$137.18M | -$39.96M | -$14.22M |
| Depreciation & Amortization | $2.23M | $1.68M | $1.1M | $717K | $107K |
| Deferred Income Tax | $0 | $0 | $8.58M | $656K | $0 |
| Stock-Based Compensation | $8K | $8.71M | $30.41M | $1.01M | $1.23M |
| Changes in Working Capital: | |||||
| Accounts Receivable | -$1K | -$21K | $26K | -$26K | -$146K |
| Inventory | $0 | $21K | $8.43M | -$244K | $146K |
| Accounts Payable | -$3.51M | $2.1M | $2.17M | -$267K | -$446K |
| Other Working Capital | -$5.03M | $7.72M | $10.71M | -$2.25M | $603K |
| Total Working Capital Change | -$8.54M | $9.82M | $12.88M | -$2.79M | $157K |
| Other Non-Cash Items | $6M | -$926K | $3.21M | $6.45M | $462K |
| Net Cash from Operating | -$57.24M | -$55.93M | -$80.99M | -$33.91M | -$12.27M |
| Investing Activities | |||||
| Capital Expenditures | -$803K | -$1.87M | -$1.32M | -$1.48M | $0 |
| Acquisitions | $0 | $52.53M | $0 | $0 | $0 |
| Purchases of Investments | -$63.94M | -$107.53M | $0 | $0 | $0 |
| Sales of Investments | $93.59M | $55M | $0 | $0 | $0 |
| Other Investing Activities | $0 | -$52.53M | $0 | $0 | $0 |
| Net Cash from Investing | $28.84M | -$54.39M | -$1.32M | -$1.48M | $0 |
| Financing Activities | |||||
| Debt Repaid | $1.59M | $430K | $771K | -$6.59M | -$11.12M |
| Common Stock Issuance | $454K | $263K | $71.08M | $59.81M | $17K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $454 | $263 | $3.07M | $39.09M | $17K |
| Net Cash from Financing | -$1.14M | -$167K | $196.17M | $66.11M | $11.14M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$29.53M | -$110.49M | $113.86M | $30.72M | -$1.13M |
| Supplementary Data | |||||
| Operating Cash Flow | -$57.24M | -$55.93M | -$80.99M | -$33.91M | -$12.27M |
| Capital Expenditure | -$803K | -$1.87M | -$1.32M | -$1.48M | $0 |
| Free Cash Flow | -$58.04M | -$57.79M | -$82.31M | -$35.39M | -$12.27M |
| Cash at Beginning | $34.57M | $145.06M | $31.2M | $476K | $1.6M |
| Cash at End | $5.04M | $34.57M | $145.06M | $31.2M | $476K |